Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
LPI (LP Information)' newest research report, the “NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Forecast” looks at past sales and reviews total world NASH (Non-alcoholic Steatohepatitis) Biomarkers sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH (Non-alcoholic Steatohepatitis) Biomarkers sales for 2023 through 2029. With NASH (Non-alcoholic Steatohepatitis) Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NASH (Non-alcoholic Steatohepatitis) Biomarkers industry.
This Insight Report provides a comprehensive analysis of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH (Non-alcoholic Steatohepatitis) Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH (Non-alcoholic Steatohepatitis) Biomarkers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH (Non-alcoholic Steatohepatitis) Biomarkers and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key NASH (Non-alcoholic Steatohepatitis) Biomarkers players cover GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market?
What factors are driving NASH (Non-alcoholic Steatohepatitis) Biomarkers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NASH (Non-alcoholic Steatohepatitis) Biomarkers market opportunities vary by end market size?
How does NASH (Non-alcoholic Steatohepatitis) Biomarkers break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
LPI (LP Information)' newest research report, the “NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Forecast” looks at past sales and reviews total world NASH (Non-alcoholic Steatohepatitis) Biomarkers sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH (Non-alcoholic Steatohepatitis) Biomarkers sales for 2023 through 2029. With NASH (Non-alcoholic Steatohepatitis) Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NASH (Non-alcoholic Steatohepatitis) Biomarkers industry.
This Insight Report provides a comprehensive analysis of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH (Non-alcoholic Steatohepatitis) Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH (Non-alcoholic Steatohepatitis) Biomarkers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH (Non-alcoholic Steatohepatitis) Biomarkers and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key NASH (Non-alcoholic Steatohepatitis) Biomarkers players cover GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Others
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GENFIT SA
- Gilead Sciences, Inc. (GILD)
- AstraZeneca
- Novartis AG
- Bristol-Myers Squibb Company
- Allergan Plc
- Novo Nordisk A/S
- Boehringer Ingelheim
- Pfizer Inc
What is the 10-year outlook for the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market?
What factors are driving NASH (Non-alcoholic Steatohepatitis) Biomarkers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NASH (Non-alcoholic Steatohepatitis) Biomarkers market opportunities vary by end market size?
How does NASH (Non-alcoholic Steatohepatitis) Biomarkers break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country/Region, 2018, 2022 & 2029
2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Type
2.2.1 Serum Biomarkers
2.2.2 Hepatic Fibrosis Biomarkers
2.2.3 Apoptosis Biomarkers
2.2.4 Oxidative Stress Biomarkers
2.2.5 Others
2.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
2.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
2.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Type (2018-2023)
2.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023)
2.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Application
2.4.1 Pharma & CRO Industry
2.4.2 Hospitals
2.4.3 Diagnostic Labs
2.4.4 Academic Research Institutes
2.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
2.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Market Share by Application (2018-2023)
2.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Application (2018-2023)
2.5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023)
3 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY COMPANY
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Breakdown Data by Company
3.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Company (2018-2023)
3.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Company (2018-2023)
3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023)
3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)
3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company
3.4 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Location Distribution
3.4.2 Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION
4.1 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Geographic Region (2018-2023)
4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Geographic Region (2018-2023)
4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country/Region (2018-2023)
4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Country/Region (2018-2023)
4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Country/Region (2018-2023)
4.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.4 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.6 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
5 AMERICAS
5.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country
5.1.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
5.1.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
5.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
5.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region
6.1.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023)
6.1.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023)
6.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
6.3 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
7.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
7.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
7.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
8.1.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
8.1.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
8.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
8.3 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
10.3 Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
10.4 Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
11.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer
12 WORLD FORECAST REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION
12.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Forecast by Region
12.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Region (2024-2029)
12.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Type
12.7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GENFIT SA
13.1.1 GENFIT SA Company Information
13.1.2 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 GENFIT SA Main Business Overview
13.1.5 GENFIT SA Latest Developments
13.2 Gilead Sciences, Inc. (GILD)
13.2.1 Gilead Sciences, Inc. (GILD) Company Information
13.2.2 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Gilead Sciences, Inc. (GILD) Main Business Overview
13.2.5 Gilead Sciences, Inc. (GILD) Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Information
13.5.2 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol-Myers Squibb Company Main Business Overview
13.5.5 Bristol-Myers Squibb Company Latest Developments
13.6 Allergan Plc
13.6.1 Allergan Plc Company Information
13.6.2 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Allergan Plc Main Business Overview
13.6.5 Allergan Plc Latest Developments
13.7 Novo Nordisk A/S
13.7.1 Novo Nordisk A/S Company Information
13.7.2 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novo Nordisk A/S Main Business Overview
13.7.5 Novo Nordisk A/S Latest Developments
13.8 Boehringer Ingelheim
13.8.1 Boehringer Ingelheim Company Information
13.8.2 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Boehringer Ingelheim Main Business Overview
13.8.5 Boehringer Ingelheim Latest Developments
13.9 Pfizer Inc
13.9.1 Pfizer Inc Company Information
13.9.2 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Pfizer Inc Main Business Overview
13.9.5 Pfizer Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country/Region, 2018, 2022 & 2029
2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Type
2.2.1 Serum Biomarkers
2.2.2 Hepatic Fibrosis Biomarkers
2.2.3 Apoptosis Biomarkers
2.2.4 Oxidative Stress Biomarkers
2.2.5 Others
2.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
2.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
2.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Type (2018-2023)
2.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023)
2.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Application
2.4.1 Pharma & CRO Industry
2.4.2 Hospitals
2.4.3 Diagnostic Labs
2.4.4 Academic Research Institutes
2.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
2.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Market Share by Application (2018-2023)
2.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Application (2018-2023)
2.5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023)
3 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY COMPANY
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Breakdown Data by Company
3.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Company (2018-2023)
3.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Company (2018-2023)
3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023)
3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)
3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company
3.4 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Location Distribution
3.4.2 Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION
4.1 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Geographic Region (2018-2023)
4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Geographic Region (2018-2023)
4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country/Region (2018-2023)
4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Country/Region (2018-2023)
4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Country/Region (2018-2023)
4.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.4 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
4.6 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth
5 AMERICAS
5.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country
5.1.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
5.1.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
5.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
5.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region
6.1.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023)
6.1.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023)
6.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
6.3 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
7.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
7.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
7.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
8.1.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
8.1.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
8.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
8.3 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
10.3 Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
10.4 Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
11.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer
12 WORLD FORECAST REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION
12.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Forecast by Region
12.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Region (2024-2029)
12.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Type
12.7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GENFIT SA
13.1.1 GENFIT SA Company Information
13.1.2 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 GENFIT SA Main Business Overview
13.1.5 GENFIT SA Latest Developments
13.2 Gilead Sciences, Inc. (GILD)
13.2.1 Gilead Sciences, Inc. (GILD) Company Information
13.2.2 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Gilead Sciences, Inc. (GILD) Main Business Overview
13.2.5 Gilead Sciences, Inc. (GILD) Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Information
13.5.2 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol-Myers Squibb Company Main Business Overview
13.5.5 Bristol-Myers Squibb Company Latest Developments
13.6 Allergan Plc
13.6.1 Allergan Plc Company Information
13.6.2 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Allergan Plc Main Business Overview
13.6.5 Allergan Plc Latest Developments
13.7 Novo Nordisk A/S
13.7.1 Novo Nordisk A/S Company Information
13.7.2 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novo Nordisk A/S Main Business Overview
13.7.5 Novo Nordisk A/S Latest Developments
13.8 Boehringer Ingelheim
13.8.1 Boehringer Ingelheim Company Information
13.8.2 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Boehringer Ingelheim Main Business Overview
13.8.5 Boehringer Ingelheim Latest Developments
13.9 Pfizer Inc
13.9.1 Pfizer Inc Company Information
13.9.2 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
13.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Pfizer Inc Main Business Overview
13.9.5 Pfizer Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Serum Biomarkers
Table 4. Major Players of Hepatic Fibrosis Biomarkers
Table 5. Major Players of Apoptosis Biomarkers
Table 6. Major Players of Oxidative Stress Biomarkers
Table 7. Major Players of Others
Table 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Table 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2018-2023) & ($ million)
Table 11. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)
Table 12. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Table 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2018-2023)
Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2018-2023)
Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Company (2018-2023) & (K Units)
Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)
Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023) ($ Millions)
Table 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)
Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution and Sales Area
Table 24. Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
Table 25. NASH (Non-alcoholic Steatohepatitis) Biomarkers Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Geographic Region (2018-2023)
Table 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country/Region (2018-2023)
Table 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 37. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 38. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 42. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023) & (K Units)
Table 43. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2018-2023)
Table 44. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2018-2023)
Table 46. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 47. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 52. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 53. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 61. Key Market Challenges & Risks of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 62. Key Industry Trends of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 63. NASH (Non-alcoholic Steatohepatitis) Biomarkers Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List
Table 66. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer List
Table 67. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. GENFIT SA Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 82. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 83. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. GENFIT SA Main Business
Table 85. GENFIT SA Latest Developments
Table 86. Gilead Sciences, Inc. (GILD) Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 87. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 88. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Gilead Sciences, Inc. (GILD) Main Business
Table 90. Gilead Sciences, Inc. (GILD) Latest Developments
Table 91. AstraZeneca Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 92. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 93. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. AstraZeneca Main Business
Table 95. AstraZeneca Latest Developments
Table 96. Novartis AG Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 98. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Novartis AG Main Business
Table 100. Novartis AG Latest Developments
Table 101. Bristol-Myers Squibb Company Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 102. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 103. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Bristol-Myers Squibb Company Main Business
Table 105. Bristol-Myers Squibb Company Latest Developments
Table 106. Allergan Plc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 107. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 108. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Allergan Plc Main Business
Table 110. Allergan Plc Latest Developments
Table 111. Novo Nordisk A/S Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 112. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 113. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Novo Nordisk A/S Main Business
Table 115. Novo Nordisk A/S Latest Developments
Table 116. Boehringer Ingelheim Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 117. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 118. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Boehringer Ingelheim Main Business
Table 120. Boehringer Ingelheim Latest Developments
Table 121. Pfizer Inc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 122. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 123. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Pfizer Inc Main Business
Table 125. Pfizer Inc Latest Developments
Table 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Serum Biomarkers
Table 4. Major Players of Hepatic Fibrosis Biomarkers
Table 5. Major Players of Apoptosis Biomarkers
Table 6. Major Players of Oxidative Stress Biomarkers
Table 7. Major Players of Others
Table 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Table 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2018-2023) & ($ million)
Table 11. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)
Table 12. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Table 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2018-2023)
Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2018-2023)
Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Company (2018-2023) & (K Units)
Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)
Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023) ($ Millions)
Table 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)
Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution and Sales Area
Table 24. Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
Table 25. NASH (Non-alcoholic Steatohepatitis) Biomarkers Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Geographic Region (2018-2023)
Table 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country/Region (2018-2023)
Table 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 37. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 38. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 42. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023) & (K Units)
Table 43. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2018-2023)
Table 44. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2018-2023)
Table 46. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 47. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 52. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 53. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 61. Key Market Challenges & Risks of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 62. Key Industry Trends of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Table 63. NASH (Non-alcoholic Steatohepatitis) Biomarkers Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List
Table 66. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer List
Table 67. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. GENFIT SA Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 82. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 83. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. GENFIT SA Main Business
Table 85. GENFIT SA Latest Developments
Table 86. Gilead Sciences, Inc. (GILD) Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 87. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 88. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Gilead Sciences, Inc. (GILD) Main Business
Table 90. Gilead Sciences, Inc. (GILD) Latest Developments
Table 91. AstraZeneca Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 92. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 93. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. AstraZeneca Main Business
Table 95. AstraZeneca Latest Developments
Table 96. Novartis AG Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 98. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Novartis AG Main Business
Table 100. Novartis AG Latest Developments
Table 101. Bristol-Myers Squibb Company Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 102. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 103. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Bristol-Myers Squibb Company Main Business
Table 105. Bristol-Myers Squibb Company Latest Developments
Table 106. Allergan Plc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 107. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 108. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Allergan Plc Main Business
Table 110. Allergan Plc Latest Developments
Table 111. Novo Nordisk A/S Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 112. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 113. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Novo Nordisk A/S Main Business
Table 115. Novo Nordisk A/S Latest Developments
Table 116. Boehringer Ingelheim Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 117. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 118. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Boehringer Ingelheim Main Business
Table 120. Boehringer Ingelheim Latest Developments
Table 121. Pfizer Inc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors
Table 122. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
Table 123. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Pfizer Inc Main Business
Table 125. Pfizer Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Serum Biomarkers
Figure 10. Product Picture of Hepatic Fibrosis Biomarkers
Figure 11. Product Picture of Apoptosis Biomarkers
Figure 12. Product Picture of Oxidative Stress Biomarkers
Figure 13. Product Picture of Others
Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type in 2022
Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)
Figure 16. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Pharma & CRO Industry
Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Pharma & CRO Industry (2018-2023) & (K Units)
Figure 18. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Hospitals
Figure 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Hospitals (2018-2023) & (K Units)
Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Diagnostic Labs
Figure 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Diagnostic Labs (2018-2023) & (K Units)
Figure 22. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Academic Research Institutes
Figure 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Academic Research Institutes (2018-2023) & (K Units)
Figure 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2022)
Figure 25. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application in 2022
Figure 26. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market by Company in 2022 (K Units)
Figure 27. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company in 2022
Figure 28. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market by Company in 2022 ($ Million)
Figure 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company in 2022
Figure 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region in 2022
Figure 32. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 33. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 34. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 35. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 36. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 37. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 39. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 42. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 43. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 44. United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region in 2022
Figure 49. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Regions in 2022
Figure 50. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 51. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 52. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 56. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 60. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 61. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 62. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 63. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 64. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 69. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 72. Egypt NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers in 2022
Figure 78. Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 79. Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 80. Channels of Distribution
Figure 81. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Forecast by Region (2024-2029)
Figure 82. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Serum Biomarkers
Figure 10. Product Picture of Hepatic Fibrosis Biomarkers
Figure 11. Product Picture of Apoptosis Biomarkers
Figure 12. Product Picture of Oxidative Stress Biomarkers
Figure 13. Product Picture of Others
Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type in 2022
Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)
Figure 16. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Pharma & CRO Industry
Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Pharma & CRO Industry (2018-2023) & (K Units)
Figure 18. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Hospitals
Figure 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Hospitals (2018-2023) & (K Units)
Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Diagnostic Labs
Figure 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Diagnostic Labs (2018-2023) & (K Units)
Figure 22. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Academic Research Institutes
Figure 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Academic Research Institutes (2018-2023) & (K Units)
Figure 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2022)
Figure 25. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application in 2022
Figure 26. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market by Company in 2022 (K Units)
Figure 27. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company in 2022
Figure 28. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market by Company in 2022 ($ Million)
Figure 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company in 2022
Figure 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region in 2022
Figure 32. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 33. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 34. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 35. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 36. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 37. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)
Figure 39. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 ($ Millions)
Figure 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 42. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 43. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 44. United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region in 2022
Figure 49. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Regions in 2022
Figure 50. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 51. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 52. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 56. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 60. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 61. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 62. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 63. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 64. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022
Figure 69. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
Figure 72. Egypt NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers in 2022
Figure 78. Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 79. Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 80. Channels of Distribution
Figure 81. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Forecast by Region (2024-2029)
Figure 82. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Application (2024-2029)
